Cargando…
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
Effective vaccines and monoclonal antibodies have been developed against coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). However, the appearance of virus variants with higher transmissibility and pathogenicity is a major concern because of...
Autores principales: | Schulz, Sebastian R., Hoffmann, Markus, Roth, Edith, Pracht, Katharina, Burnett, Deborah L., Mazigi, Ohan, Schuh, Wolfgang, Manger, Bernhard, Mielenz, Dirk, Goodnow, Christopher C., Christ, Daniel, Pöhlmann, Stefan, Jäck, Hans‐Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087419/ https://www.ncbi.nlm.nih.gov/pubmed/35253229 http://dx.doi.org/10.1002/eji.202249841 |
Ejemplares similares
-
A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model
por: Peter, Antonia Sophia, et al.
Publicado: (2021) -
Neutralizing antibodies to SARS‐CoV‐2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects
por: Haveri, Anu, et al.
Publicado: (2022) -
Neutralizing antibody responses 300 days after SARS‐CoV‐2 infection and induction of high antibody titers after vaccination
por: Urlaub, Doris, et al.
Publicado: (2022) -
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
por: Haveri, Anu, et al.
Publicado: (2021) -
Non‐neutralizing antibodies protect against chronic LCMV infection by promoting infection of inflammatory monocytes in mice
por: Stoycheva, Diana, et al.
Publicado: (2021)